Aurobindo Pharma saw an 8.6% increase in its consolidated net profit for the September quarter, reaching ₹816.9 crore compared to ₹751.9 crore the previous year. Despite this growth, the net profit was 11% lower sequentially from the ₹918.2 crore reported in the June quarter. The company also experienced an 8.0% year-on-year increase in total revenue from operations, totaling ₹7,796 crore compared to ₹7,219 crore, with a 3% increase from the first quarter’s revenue of ₹7,567 crore. This growth in revenue was driven by the mainstay formulations business, which contributed ₹6,640 crore, marking an 11.3% increase year-on-year. Additionally, the formulations revenue in the September quarter received a boost from a 19% growth in Europe, a 44% increase in Growth Markets, and a 4.3% increase in the key U.S. market.
Despite a slight dip in profitability due to certain transient business activities, the company’s underlying performance remains strong, according to vice-chairman and managing director K. Nithyananda Reddy. He expressed confidence in the company’s ability to maintain its growth trajectory and achieve strategic objectives for the year. The revenue from the Active Pharmaceutical Ingredient segment declined slightly year-on-year but showed a 5.9% increase sequentially.
With continued growth in revenues across key business areas, Aurobindo Pharma demonstrates the resilience of its diversified portfolio. The company’s solid foundation and ongoing operational improvements position it well for future success. As it navigates through transient challenges, Aurobindo Pharma remains committed to delivering value to its stakeholders and driving sustainable growth.